Advanced Search

Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2015 September;57(3) > Panminerva Medica 2015 September;57(3):121-5

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEPANMINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6

 

Panminerva Medica 2015 September;57(3):121-5

 ORIGINAL ARTICLES

Recurrence of retinal vein thrombosis with Pycnogenol® or Aspirin® supplementation: a registry study

Rodriguez P., Belcaro G., Dugall M., Hu S., Luzzi R., Ledda A., Ippolito E., Corsi M., Ricci A., Feragalli B., Cornelli U., Gizzi C., Hosoi M.

Department of Biomedical Sciences, Irvine3 Labs, Circulation Sciences, Chieti‑Pescara University, Italy

AIM: The aim of this study was to use Pycnogenol® to reduce the recurrence of retinal vein thrombosis (RVT) after a first episode. Pycnogenol® is an anti-inflammatory, anti-edema and an antiplatelet agent with a “mild” antithrombotic activity. The registry, using Pycnogenol® was aimed at reducing the number of repeated episodes of RVT.
METHODS: Possible management options – chosen by patients – were: standard management; standard management + oral Aspirin® 100 mg once/day (if there were no tolerability problems before admission); standard management + Pycnogenol® two 50 mg capsules per day (for a total of 100 mg/day). Number of subjects, age, sex, distribution, percentage of smokers, and vision were comparable.
RESULTS: Recurrent RVT was seen in 17.39% of controls and in 3.56% of subjects supplemented with Pycnogenol® (P<0.05 vs. controls). There was RVT in 15.38% of the subjects using Aspirin®. The incidence of RVT was 4.88 times higher with standard management in comparison with the supplement group and 4.32 lower with Pycnogenol® supplementation in comparison with Aspirin®. Vision level was better with Pycnogenol® (20/25 at nine months; P<0.05). With Pycnogenol®, edema at the retinal level was also significantly reduced compared to the other groups. Pycnogenol® has a very good safety profile. In the Aspirin® group 26 completed 9 months and 6 subjects dropped out for tolerability problems. In the Aspirin® group, 2 minor, subclinical, retinal, hemorrhagic episodes during the follow-up were observed (2 subjects out of 26, equivalent to 7.69%). This pilot registry indicates that Pycnogenol® seems to reduce the recurrence of RVT without side effects. It does not induce new hemorrhagic episodes that may be theoretically linked to the use of Aspirin® (or other antiplatelets).
CONCLUSION: Larger studies should be planned involving a wider range of conditions, diseases and risk factors associated to RVT and to its recurrence.

language: English


FULL TEXT  REPRINTS

top of page